Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 0.71 |
| ▸ | PDE4A | P27815 | 5/20 | 0.71 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.71 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1572502 | 1.00 | PDE4B (0.71) | PDE4BPDE4APDE4CPDE4DCTSK | |
| SCHEMBL27481581 | 0.99 | PDE4B (0.70) | PDE4BPDE4APDE4CPDE4DCTSK | |
| SCHEMBL15040911 | 0.83 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5184039 | 0.83 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7365382 | 0.81 | PDE4B (0.82) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5708642 | 0.80 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6811981 | 0.79 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6811975 | 0.79 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6811984 | 0.79 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7360513 | 0.79 | PDE4B (0.82) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176221-B1 | INDOLE INDANE AMIDE COMPOUNDS USEFUL AS CB2 AGONISTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2011-04-13 | — | — | EP | claimed |
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280952-A1 | Pyridine Derivatives as Connabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| US-20060019963-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2006-01-26 | — | — | US | disclosed |
| EP-1466598-A2 | PDE-IV inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-0710109-B1 | Method for identifying a PDE IV inhibitor | SMITHKLINE BEECHAM CORP (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6555583-B2 | Therapies for treating pulmonary diseases | SMITHKLINE BEECHAM CORPORATION | 2003-04-29 | — | — | US | disclosed |
| US-20020115111-A1 | Enzymatic polypeptide for use in the treatment of inflammation | SMITHKLINE BEECHAM CORPORATION | 2002-08-22 | — | — | US | disclosed |
| US-20010056122-A1 | Therapies for treating pulmonary diseases | SMITHKLINE BEECHAM CORPORATION | 2001-12-27 | — | — | US | disclosed |
| US-6288118-B1 | Therapies for treating pulmonary diseases | SMITHKLINE BEECHAM CORPORATION | 2001-09-11 | — | — | US | disclosed |
| EP-1107747-A1 | THERAPIES FOR TREATING PULMONARY DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6143782-A | BRONCHODILATOR FOR INHIBITING PDE IV CATALYSTS AND BINDING RROLIPRAM AND ADMINISTERING | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| WO-2000012078-A1 | THERAPIES FOR TREATING PULMONARY DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-09 | — | — | WO | disclosed |
| US-5998428-A | ANTIINFLAMMATORY AGENT; SIDE EFFECT REDUCTION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0710109-A4 | COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0710109-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-05-08 | — | — | EP | disclosed |
| WO-1995000139-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | CNR2, CNR1, TRPV1 | PDE4B 980/4885PDE4A 1040/4885PDE4C 1372/4885 |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | CNR2, CNR1, TRPV1 | PDE4B 1074/4885PDE4A 894/4885PDE4C 1366/4885 |
| US-20080280952-A1 | Pyridine Derivatives as Connabinoid Receptor Modulators | CNR1, CNR2, P2RY1 | PDE4B 1531/4885PDE4A 1827/4885PDE4C 2514/4885 |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | CNR2, CNR1, PDE4A | PDE4B 4/4885PDE4A 3/4885PDE4C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.